74061-79-3
Chemical Structure
Sesaminol
- CAS No.: 74061-79-3
- Formula:C20H18O7
- Molecular Weight:370.35
InChIKey: KQRXQIPRDKVZPW-ISZNXKAUSA-N
SMILES: OC1=C(C=C2C(OCO2)=C1)[C@@H]3[C@]4([H])[C@@](CO3)([H])[C@@H](C5=CC=C(OCO6)C6=C5)OC4
Biological Activity: Sesaminol is an orally active antioxidant. Sesaminol induces G1 phase arrest and inhibits cancer cell growth by binding to ANT2, inhibiting mTORC1, and promoting cyclin D1 degradation; it also activates Nrf2/NQO1, inhibits ROS- and neurotoxin-induced apoptosis (apoptosis), reduces α-synuclein (α-synuclein) and Aβ oligomerization/fibril formation, and promotes M2 microglial polarization. Sesaminol can be used in research on cancer, Parkinson's disease, obesity, Alzheimer's disease, colitis, cognitive decline, and liver diseases[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sesaminol | Sesaminol is an orally active antioxidant. Sesaminol induces G1 phase arrest and inhibits cancer cell growth by binding to ANT2, inhibiting mTORC1, and promoting cyclin D1 degradation; it also activates Nrf2/NQO1, inhibits ROS- and neurotoxin-induced apoptosis (apoptosis), reduces α-synuclein (α-synuclein) and Aβ oligomerization/fibril formation, and promotes M2 microglial polarization. Sesaminol can be used in research on cancer, Parkinson's disease, obesity, Alzheimer's disease, colitis, cognitive decline, and liver diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Watanabe M, et al. The pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2. Oncogenesis. 2017 Apr 03;6(4):e311.
- [2]. Sheng H, et al. Modifying effect of dietary sesaminol glucosides on the formation of azoxymethane-induced premalignant lesions of rat colon. Cancer letters. 2007 Feb 08;246(1-2):63-8.
- [3]. Kaji H, et al. Sesaminol prevents Parkinson's disease by activating the Nrf2-ARE signaling pathway. Heliyon. 2020 Nov;6(11):e05342. [Content Brief]
- [4]. Divakaran SJ, et al. Sesaminol induces brown and beige adipocyte formation through suppression of myogenic program. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2020 May;34(5):6854-6870.
- [5]. Katayama S, et al. Effects of Sesaminol Feeding on Brain Aβ Accumulation in a Senescence-Accelerated Mouse-Prone 8. Journal of agricultural and food chemistry. 2016 Jun 22;64(24):4908-13.
- [6]. Nakamatsu S, et al. Sesaminol Inhibits Adipogenesis by Suppressing Mitotic Clonal Expansion and Activating the Nrf2-ARE Pathway. Nutrients. 2025 Oct 15;17(20):3242.
- [7]. Ohira H, et al. Suppression of colonic oxidative stress caused by chronic ethanol administration and attenuation of ethanol-induced colitis and gut leakiness by oral administration of sesaminol in mice. Food & function. 2022 Sep 22;13(18):9285-9298.
- [8]. Zheng L, et al. Sesaminol Ameliorates Age-Related Cognitive Decline and Neuroinflammation by Modulating Microglial Polarization and Enhancing Aβ Phagocytosis in Mice. Journal of agricultural and food chemistry. 2026 Feb 04;74(4):3624-3641.
- [9]. Zheng L, et al. Sesaminol Ameliorates Metabolic and Alcohol-Related Liver Injury by Activating the PPARα/Slc27a5 Axis-Driven Hepatic Fatty Acid β-Oxidation. Molecular nutrition & food research. 2026 May;70(10):e70506. [Content Brief]
- [10]. Rajendran R, et al. Sesaminol alters phospholipid metabolism and alleviates obesity-induced NAFLD. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2024 Jul 31;38(14):e23835.
